153 related articles for article (PubMed ID: 8727601)
1. Epstein-Barr virus and the B cell: that's all it takes.
Thorley-Lawson DA; Miyashita EM; Khan G
Trends Microbiol; 1996 May; 4(5):204-8. PubMed ID: 8727601
[TBL] [Abstract][Full Text] [Related]
2. Epstein-Barr virus immortalization and latency.
Rowe DT
Front Biosci; 1999 Mar; 4():D346-71. PubMed ID: 10077545
[TBL] [Abstract][Full Text] [Related]
3. Non-correlation of in vivo and in vitro parameters of Epstein-Barr virus persistence suggests heterogeneity of B cell infection.
Johannessen I; Haque T; N'Jie-Jobe J; Crawford DH
J Gen Virol; 1998 Jul; 79 ( Pt 7)():1631-6. PubMed ID: 9680124
[TBL] [Abstract][Full Text] [Related]
4. Characterization of natural Epstein-Barr virus infection and replication in smooth muscle cells from a leiomyosarcoma.
Jenson HB; Montalvo EA; McClain KL; Ench Y; Heard P; Christy BA; Dewalt-Hagan PJ; Moyer MP
J Med Virol; 1999 Jan; 57(1):36-46. PubMed ID: 9890420
[TBL] [Abstract][Full Text] [Related]
5. Differential methylation of Epstein-Barr virus latency promoters facilitates viral persistence in healthy seropositive individuals.
Paulson EJ; Speck SH
J Virol; 1999 Dec; 73(12):9959-68. PubMed ID: 10559309
[TBL] [Abstract][Full Text] [Related]
6. Notch and Wnt signaling: mimicry and manipulation by gamma herpesviruses.
Hayward SD; Liu J; Fujimuro M
Sci STKE; 2006 May; 2006(335):re4. PubMed ID: 16705130
[TBL] [Abstract][Full Text] [Related]
7. Regulation of Epstein-Barr virus latency by latent membrane protein 2.
Longnecker R; Miller CL
Trends Microbiol; 1996 Jan; 4(1):38-42. PubMed ID: 8824794
[TBL] [Abstract][Full Text] [Related]
8. The role of Epstein-Barr virus in lymphoid malignancies.
Su IJ; Chen JY
Crit Rev Oncol Hematol; 1997 May; 26(1):25-41. PubMed ID: 9246539
[No Abstract] [Full Text] [Related]
9. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
Niller HH; Wolf H; Minarovits J
Autoimmunity; 2008 May; 41(4):298-328. PubMed ID: 18432410
[TBL] [Abstract][Full Text] [Related]
10. Epstein-Barr virus (EBV) nuclear antigen 6 induces expression of the EBV latent membrane protein and an activated phenotype in Raji cells.
Allday MJ; Crawford DH; Thomas JA
J Gen Virol; 1993 Mar; 74 ( Pt 3)():361-9. PubMed ID: 8383171
[TBL] [Abstract][Full Text] [Related]
11. Epstein-Barr virus recombinants from BC-1 and BC-2 can immortalize human primary B lymphocytes with different levels of efficiency and in the absence of coinfection by Kaposi's sarcoma-associated herpesvirus.
Aguirre AJ; Robertson ES
J Virol; 2000 Jan; 74(2):735-43. PubMed ID: 10623735
[TBL] [Abstract][Full Text] [Related]
12. Identification of MEF2B, EBF1, and IL6R as Direct Gene Targets of Epstein-Barr Virus (EBV) Nuclear Antigen 1 Critical for EBV-Infected B-Lymphocyte Survival.
Tempera I; De Leo A; Kossenkov AV; Cesaroni M; Song H; Dawany N; Showe L; Lu F; Wikramasinghe P; Lieberman PM
J Virol; 2016 Jan; 90(1):345-55. PubMed ID: 26468528
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus coinfection and recombination in non-human immunodeficiency virus-associated oral hairy leukoplakia.
Walling DM; Clark NM; Markovitz DM; Frank TS; Braun DK; Eisenberg E; Krutchkoff DJ; Felix DH; Raab-Traub N
J Infect Dis; 1995 May; 171(5):1122-30. PubMed ID: 7751686
[TBL] [Abstract][Full Text] [Related]
14. Isolation of cytotoxic T lymphocytes from healthy seropositive individuals specific for peptide epitopes from Epstein-Barr virus nuclear antigen 1: implications for viral persistence and tumor surveillance.
Khanna R; Burrows SR; Steigerwald-Mullen PM; Thomson SA; Kurilla MG; Moss DJ
Virology; 1995 Dec; 214(2):633-7. PubMed ID: 8553567
[TBL] [Abstract][Full Text] [Related]
15. Characterization of Epstein-Barr virus-infected cells in benign lymphadenopathy of patients seropositive for human immunodeficiency virus.
Brousset P; Schlaifer D; Roda D; Massip P; Marchou B; Delsol G
Hum Pathol; 1996 Mar; 27(3):263-8. PubMed ID: 8600041
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1.
Levitskaya J; Sharipo A; Leonchiks A; Ciechanover A; Masucci MG
Proc Natl Acad Sci U S A; 1997 Nov; 94(23):12616-21. PubMed ID: 9356498
[TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr virus and the immune system. Hide and seek.
Cohen JI
JAMA; 1997 Aug; 278(6):510-3. PubMed ID: 9256227
[No Abstract] [Full Text] [Related]
18. EBV-NK cells interactions and lymphoproliferative disorders.
Kanegane H; Yachie A; Miyawaki T; Tosato G
Leuk Lymphoma; 1998 May; 29(5-6):491-8. PubMed ID: 9643562
[TBL] [Abstract][Full Text] [Related]
19. Propagation and recovery of intact, infectious Epstein-Barr virus from prokaryotic to human cells.
Delecluse HJ; Hilsendegen T; Pich D; Zeidler R; Hammerschmidt W
Proc Natl Acad Sci U S A; 1998 Jul; 95(14):8245-50. PubMed ID: 9653172
[TBL] [Abstract][Full Text] [Related]
20. Three restricted forms of Epstein-Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells.
Kelly GL; Milner AE; Baldwin GS; Bell AI; Rickinson AB
Proc Natl Acad Sci U S A; 2006 Oct; 103(40):14935-40. PubMed ID: 17001014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
